Deep Dive Into Sangamo Therapeutics Stock: Analyst Perspectives (4 Ratings)

In the last three months, 4 analysts have published ratings on Sangamo Therapeutics SGMO, offering a diverse range of perspectives from bullish to bearish.

The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.

In the assessment of 12-month price targets, analysts unveil insights for Sangamo Therapeutics, presenting an average target of $2.25, a high estimate of $3.00, and a low estimate of $1.00. A decline of 59.09% from the prior average price target is evident in the current average.

Breaking Down Analyst Ratings: A Detailed Examination

The standing of Sangamo Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Sangamo Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.
• Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Sangamo Therapeutics compared to the broader market.
• Price Targets: Delving into movements, analysts provide estimates for the future value of Sangamo Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.

For valuable insights into Sangamo Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.

Stay up to date on Sangamo Therapeutics analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Delving into Sangamo Therapeutics's Background

Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemophilia, Central Nervous System, HIV, Lysosomal Storage Disorders, and Hemoglobinopathies.

Understanding the Numbers: Sangamo Therapeutics's Finances

Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.

Decline in Revenue: Over the 3 months period, Sangamo Therapeutics faced challenges, resulting in a decline of approximately -64.48% in revenue growth as of 30 September, 2023. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Sangamo Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -1108.35% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): Sangamo Therapeutics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -56.52%, the company may face hurdles in achieving optimal financial performance.

Return on Assets (ROA): Sangamo Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -38.24%, the company may face hurdles in generating optimal returns from its assets.

Debt Management: Sangamo Therapeutics's debt-to-equity ratio is below the industry average at 0.26, reflecting a lower dependency on debt financing and a more conservative financial approach.

The Core of Analyst Ratings: What Every Investor Should Know

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.

This article was generated by Benzinga's automated content engine and reviewed by an editor.